Skip to main content
Xspray Pharma logo

Xspray Pharma — Investor Relations & Filings

Ticker · XSPRAY ISIN · SE0023312764 LEI · 549300NGRQCNZ3X4L157 ST Manufacturing
Open in API
Filings indexed 254 across all filing types
Latest filing 2020-10-20 Capital/Financing Update
Country SE Sweden
Listing ST XSPRAY

About Xspray Pharma

https://xspraypharma.com/

Xspray Pharma is a pharmaceutical company that utilizes its patented technology platform to develop improved versions of marketed drugs, primarily focusing on Protein Kinase Inhibitors (PKIs) for cancer treatment. The company's core innovation lies in its ability to create stable, amorphous (non-crystalline) formulations of active pharmaceutical ingredients. This unique approach enables the development of product candidates that can bypass the secondary patents of original crystalline drugs, facilitating market entry upon the expiration of the primary substance patent. Xspray Pharma's products are designed to offer clinical benefits for patients compared to the original branded drugs and their subsequent generic equivalents.

Recent filings

Filing Released Lang Actions
Xspray Pharma Has Carried Out a Directed Share Issue Raising Gross Proceeds of Approximately SEK 265 million
Capital/Financing Update Classification · 98% confidence The document is a press release announcing that Xspray Pharma AB has successfully carried out a 'directed share issue' raising approximately SEK 265 million. This action involves the issuance of new shares to institutional investors to raise capital. This directly relates to changes in the company's capital structure and fundraising activities. Based on the definitions, the most appropriate classification is 'Capital/Financing Update' (CAP). Although it involves shares, it is a financing event announcement, not a general share repurchase (POS) or a general share issue announcement (SHA), but specifically a capital raise via a share issue. The document is a full announcement, not just a notice that a report is attached, so RPA/RNS is less specific than CAP.
2020-10-20 English
Xspray Pharma har genomfört en riktad emission som tillför bolaget cirka 265 MSEK
Capital/Financing Update Classification · 98% confidence The document is a press release from Xspray Pharma AB announcing the successful completion of a directed share issue ('riktad emission') that raised approximately 265 MSEK. The text details the subscription price, participating institutional investors, the intended use of the net proceeds (funding product development, finalizing production facilities, and general operations), and the resulting dilution (approx. 10%). This clearly falls under corporate financing activities, specifically the issuance of new shares to raise capital. This aligns directly with the definition for Capital/Financing Update (CAP). Although it involves shares, it is an announcement of a capital raise, not a report of the company buying back its own shares (POS) or a general share issue/split announcement (SHA), but rather a specific financing event.
2020-10-20 Swedish
Xspray Pharma överväger en riktad emission
Capital/Financing Update Classification · 100% confidence The document is a press release from Xspray Pharma AB announcing that the company is considering a directed share issue (private placement) to institutional investors via an accelerated bookbuilding process. It details the purpose of the capital raise, the involvement of financial advisors, and legal disclaimers regarding the offering. This falls under the category of capital/financing updates as it pertains to fundraising and changes to the company's capital structure.
2020-10-20 Swedish
Xspray Pharma Contemplates a Directed Share Issue
Capital/Financing Update Classification · 100% confidence The document is a press release from Xspray Pharma AB announcing the company's intention to conduct a directed share issue (an accelerated bookbuild transaction). It details the purpose of the capital raise, the involvement of joint bookrunners, and the lock-up undertakings. This falls squarely under the definition of a Capital/Financing Update (CAP), as it describes a specific fundraising activity and changes to the company's capital structure.
2020-10-20 English
Antal aktier och röster i Xspray
Share Issue/Capital Change Classification · 99% confidence The document explicitly announces a change in the number of outstanding shares and votes due to the exercise of stock options ('utnyttjande av teckningsoptioner'). This directly relates to a change in the company's capital structure and share count. This fits the definition of 'Share Issue/Capital Change' (SHA). Although it is a short announcement, the core subject is the capital change itself, not just the announcement of a report, making SHA more specific than RPA or RNS. The final sentence confirms it is information the company is obliged to disclose ('skyldigt att offentliggöra').
2020-09-30 Swedish
Number of shares and votes in Xspray
Share Issue/Capital Change Classification · 98% confidence The document explicitly announces a change in the number of outstanding shares and votes due to the exercise of warrants. This directly relates to changes in the company's capital structure (share count and share capital increase). This aligns perfectly with the definition of 'Share Issue/Capital Change' (SHA). Although it is a short announcement, the content is substantive regarding capital structure, making SHA more specific than a general RPA or RNS. The document is not a general regulatory filing fallback because a specific category exists for capital changes.
2020-09-30 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.